AUTHORS
Isabel Vallecillo-Viejo, MD, PhD, Christi Salisbury-Ruf, PhD2, Mohd Azhar, PhD3, Fariba Chinian4, Andre Larochelle, MD, PhD5
AFFILIATIONS
1 National Institiutes of Health, Bethesda, Maryland, United States
2 National Institiutes of Health, Bethesda, Maryland, United States
3 National Institiutes of Health, Bethesda, Maryland, United States
4 National Institiutes of Health, Bethesda, Maryland, United States
5 National Institiutes of Health, Bethesda, Maryland, United States
ABSTRACT
Base editing can correct pathogenic variants without generating double-strand DNA breaks, an attractive strategy for Fanconi anemia (FA), where DNA repair is defective. A limited and fragile hematopoietic stem and progenitor cell (HSPC) pool, poorly tolerant of prolonged ex vivo culture, further motivates in vivo delivery in FA. Lipid nanoparticles (LNPs) are the leading nonviral vehicle, but efficient HSPC delivery remains difficult. In circulation, LNPs acquire a serum protein corona that can redirect tropism and abolish activity, yet candidates are conventionally prioritized under serum-free conditions. We optimized RNA cargo and LNP formulation in primary human CD34+ cells and asked whether serum-free potency predicts activity under a 50% human-serum challenge.
Cryopreserved mobilized peripheral blood CD34+ cells from three healthy donors were used for optimization studies. Exploratory serum-challenge studies used cells from one CD34+ donor and non–heat-inactivated serum from three independent donors. Initial RNA cargo optimization was performed using a commercially available formulation, whereas subsequent dose-response and serum-challenge studies evaluated additional candidate LNP formulations (Cytiva). Cells were prestimulated for 24 hours with thrombopoietin, stem cell factor, and FLT3 ligand, then treated with candidate LNPs encapsulating ABE8e mRNA and a gRNA targeting the noncoding strand to install the FANCA NM_000135.4:c.2677C>T edit. This guide was used to optimize editing in healthy-donor CD34+ cells because the c.2677 site lies near the pathogenic FANCA NM_000135.4:c.2638C>T (p.Arg880*) variant targeted therapeutically. gRNAs carried terminal or extensive 2′-O-methyl-phosphorothioate modifications. Editing and viability were assessed 48 hours post-treatment by amplicon Sanger sequencing and acridine orange/propidium iodide staining, respectively. Values are mean ± SD.
At a fixed total RNA dose of 1000 ng per 200,000 cells, editing differed by ABE8e mRNA:gRNA input mass ratio (P = 0.0049; one-way repeated-measures ANOVA with Tukey’s test). Editing at a 2:1 ratio was lower (34.3 ± 7.1%) than at 1:1 (82.2 ± 6.7%, P = 0.012), 1:2 (66.5 ± 6.4%, P = 0.0065), or 1:4 (80.3 ± 5.4%, P = 0.0265); 1:1 was selected for subsequent studies. At 1:1, editor variant and guide chemistry interacted (P = 0.0177; two-way repeated-measures ANOVA with Sidak's test). Extensive guide modification increased ABE8e-V106W editing (70.2 ± 0.9% vs 88.2 ± 3.0%, P = 0.0099) but did not significantly alter parental ABE8e activity (73.6 ± 5.1% vs 72.7 ± 6.3%, P = 0.66). Viability remained >90%. ABE8e-V106W with the extensively modified gRNA was selected.
Six LNP formulations were evaluated at 5–1200 ng total RNA per 200,000 cells (n = 3). Particle diameters were 68–205 nm, polydispersity indices (PDIs) 0.03–0.26, RNA encapsulation 92–97%, and viability 89–97%; these bulk measures did not predict editing potency. LNP2 and LNP6 achieved >80% editing with 50–100 ng, whereas LNP1 required 800–1200 ng. LNP3 and LNP4 peaked at 45% and 35%, respectively, and LNP5 peaked at 60% before declining despite preserved viability.
All six formulations were then tested in 50% human serum at their maximally active serum-free RNA dose. Although LNP2 and LNP6 each achieved >80% serum-free editing, LNP2 retained 67 ± 4.3% editing across the three serum sources, whereas LNP6 and all other formulations fell to ≤10% despite preserved viability. After serum incubation, Z-average diameters were unchanged and PDI increased modestly in all six formulations, including LNP2. These changes did not track with editing outcome, indicating that serum sensitivity was not explained by aggregation and more likely reflected corona composition and uptake.
Systematic co-optimization of ABE8e mRNA:gRNA input ratio, editor–guide chemistry, and LNP formulation enabled >80% FANCA surrogate-site editing in primary human CD34+ cells at a translationally scalable RNA dose. Serum challenge re-ranked formulations with similar serum-free performance, providing a practical candidate-selection strategy and identifying LNP2 for confirmation in FA patient-derived cells and subsequent in vivo evaluation.
DISCLOSURES
Isabel Vallecillo-Viejo, MD, PhD: No relevant conflicts of interest to declare.